NL-OMON26309已完成不适用
The effect of Ivacaftor in CF patients with a class III mutation
niversity Medical Center Utrecht (UMCU)0 个研究点目标入组 10 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •CFTR genotype compound/ S1251N
- •Already had a rectal biopsy to produce an organoid
排除标准
- •Use of curcumin and or genistein at start or within two weeks prior to start of the study;
- •Inability to follow instructions of the investigator.
研究者
相似试验
已完成
4 期
The effect of Ivacaftor in CF patients with a class III mutatioMucoviscidosis10038686Cystic FibrosisNL-OMON41740niversitair Medisch Centrum Utrecht16
已完成
不适用
Ivacaftor in French Patients With Cystic Fibrosis and a G551D MutationCystic FibrosisNCT02194881Assistance Publique - Hôpitaux de Paris57
已完成
2 期
Safety Study of Ivacaftor in Subjects With Cystic FibrosisCystic FibrosisNCT00457821Vertex Pharmaceuticals Incorporated39
已完成
不适用
Pharmacokinetic interactions between ivacaftor and cytochrome P450 3A4 inhibitors in cystic fibrosis patients and healthy controlsmucoviscoidosis10083624Cystic fibrosisNL-OMON46971HagaZiekenhuis12
进行中（未招募）
1 期
The influence of cytochrome P450 3A4 inhibitors on serum levels of Ivacaftor in cystic fibrosis patients and healthy subjects.cystic fibrosis and healthy subjectsEUCTR2016-001440-18-NLuniversity medical center utrecht12